Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.
PLoS One
; 10(8): e0135963, 2015.
Article
em En
| MEDLINE
| ID: mdl-26274922
ABSTRACT
BACKGROUND AND AIMS:
Monitoring of chronic Hepatitis C (CHC) treatment relies on HCV RNA quantification by means of real-time PCR methods. Assay specific analytical sensitivities may impact therapy management.METHODS:
Comparative analysis between three commercial assays (Roche COBAS AmpliPrep/COBAS TaqMan Version 1 (CAP/CTM Ver. 1), Version 2 (CAP/CTM Ver. 2) and the Abbott RealTime HCV (ART) assay) was performed on 247 available samples taken at key decision time points during antiviral therapy of 105 genotype 1 patients (triple therapy n = 70; dual therapy n = 35).RESULTS:
Overall concordance of HCV RNA measurements was high between the two Roche systems (89%; n = 220/247) but lower between the Roche assays and the ART (CAP/CTM Ver. 1 vs ART 77.3%; n = 191/247 and CAP/CTM v.2 vs ART 80.1%; n = 198/247). Most discrepancies were noted in week 4/8 samples with residual viremia (CONCLUSION:
An abbreviated course of treatment can safely be applied in patients with residual viremia (
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
RNA Viral
/
Hepatite C Crônica
/
Reação em Cadeia da Polimerase em Tempo Real
/
Monitorização Fisiológica
Tipo de estudo:
Guideline
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
PLoS One
Assunto da revista:
CIENCIA
/
MEDICINA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Áustria